Description
The Circulating Immune Checkpoint Biomarker Panel (HDCKP1-Clin) delivers advanced profiling of immune checkpoint pathways that regulate immune activation, tolerance, and tumor immune evasion. This clinical diagnostic test enables simultaneous measurement of 17 key immune checkpoint proteins from a small sample volume, offering deep insights into immune regulation in cancer, autoimmune, and inflammatory diseases.
Immune checkpoint proteins act as either co-stimulatory or co-inhibitory signals that shape immune responses. Dysregulation of these pathways can result in immune escape in cancer or excessive immune activation in autoimmunity. By quantifying both stimulatory and inhibitory checkpoint proteins in circulation, this panel provides a clinically relevant view of immune system balance and supports precision diagnostics in immunotherapy and disease monitoring.
Indications:
Use this panel to investigate T cell activation and exhaustion, and to provide supportive information for assessing the potential suitability of checkpoint inhibitor therapies in cancer and autoimmune conditions.
Key Features:
- Comprehensive Immune Checkpoint Coverage: Simultaneous measurement of 17 checkpoint proteins, including PD-1, PD-L1, CTLA-4, TIM-3, LAG-3, and ICOS.
- Clinical Relevance: Supports diagnostic evaluation of immune dysregulation, therapeutic monitoring, and research-driven clinical applications.
- Swift Turnaround Time: We pride ourselves on a rapid turnaround time, with results typically delivered within 5 business days of receiving your specimen and payment.
- CLIA Certified for Clinical Use: As a CLIA certified laboratory, we provide a panel that meets the highest standards of accuracy and reliability for clinical diagnostics.
- Affordable Assay Services: We offer some of the most affordable assay services available, making advanced diagnostics accessible for clinical applications.
Why This Panel Matters
Checkpoint proteins such as PD-1, PD-L1, and CTLA-4 are central to cancer immunotherapy and immune regulation. Measuring helps clinicians identify immune exhaustion, monitor response to checkpoint inhibitor therapy, and evaluate immune-related adverse events.
Clinicians: Please check with your State Agency to determine if additional licensure or registration requirements may apply.
! The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.